Next Article in Journal
Endoparasites of Domesticated Animals That Originated in the Neo-Tropics (New World Tropics)
Next Article in Special Issue
Urinalysis and Urinary GGT-to-Urinary Creatinine Ratio in Dogs with Acute Pancreatitis
Previous Article in Journal
Characterization of Collagen Fibers (I, III, IV) and Elastin of Normal and Neoplastic Canine Prostatic Tissues
Previous Article in Special Issue
Attitudes toward Animals and Their Welfare among Italian Veterinary Students
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle

Intracoronary Gene Delivery of the Cytoprotective Factor Vascular Endothelial Growth Factor-B167 in Canine Patients with Dilated Cardiomyopathy: A Short-Term Feasibility Study

Department of Emergency and Organ Transplantation, Section of Veterinary Clinics and Animal Production; University of Bari, 70010 Bari; Italy
Institute of Life Sciences, Scuola Superiore Sant’Anna, 56100 Pisa, Italy
Heart Center, Dresden at the Technical University of Dresden, 01067 Dresden, Germany
Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy
CNR, Institute of Clinical Physiology, Area della Ricerca, 56121 Pisa, Italy
Author to whom correspondence should be addressed.
Vet. Sci. 2019, 6(1), 23;
Received: 14 December 2018 / Revised: 17 February 2019 / Accepted: 28 February 2019 / Published: 6 March 2019
(This article belongs to the Special Issue Italian Society of the Veterinary Sciences SISVet 2018)
PDF [1634 KB, uploaded 6 March 2019]


Dilated cardiomyopathy (DCM) is a myocardial disease of dogs and humans characterized by progressive ventricular dilation and depressed contractility and it is a frequent cause of heart failure. Conventional pharmacological therapy cannot reverse the progression of the disease and, in humans, cardiac transplantation remains the only option during the final stages of heart failure. Cytoprotective gene therapy with vascular endothelial growth factor-B167 (VEGF-B167) has proved an effective alternative therapy, halting the progression of the disease in experimental studies on dogs. The aim of this work was to test the tolerability and feasibility of intracoronary administration, under fluoroscopic guidance, of VEGF-B167 carried by adeno-associated viral vectors in canine DCM patients. Ten patients underwent the gene delivery procedure. The intraoperative phase was well tolerated by all dogs. Clinical and echocardiographic assessments at 7- and 30-days post-procedure showed stable conditions compared to the pre-procedure phase. The results of this work indicate that intracoronary VEGF-B167 gene delivery is feasible and tolerated in dogs with DCM. Further monitoring/investigations are ongoing to evaluate the effects of this therapy on disease progression. View Full-Text
Keywords: clinical study; intracoronary cytoprotective gene therapy; dogs clinical study; intracoronary cytoprotective gene therapy; dogs

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Paradies, P.; Carlucci, L.; Woitek, F.; Staffieri, F.; Lacitignola, L.; Ceci, L.; Romano, D.; Sasanelli, M.; Zentilin, L.; Giacca, M.; Salvadori, S.; Crovace, A.; Recchia, F.A. Intracoronary Gene Delivery of the Cytoprotective Factor Vascular Endothelial Growth Factor-B167 in Canine Patients with Dilated Cardiomyopathy: A Short-Term Feasibility Study. Vet. Sci. 2019, 6, 23.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vet. Sci. EISSN 2306-7381 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top